Repligen Co. (NASDAQ:RGEN) Shares Purchased by M&T Bank Corp

M&T Bank Corp raised its holdings in Repligen Co. (NASDAQ:RGEN) by 5.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,166 shares of the biotechnology company’s stock after acquiring an additional 177 shares during the quarter. M&T Bank Corp’s holdings in Repligen were worth $471,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the business. Y Intercept Hong Kong Ltd acquired a new stake in Repligen during the third quarter valued at approximately $658,000. MML Investors Services LLC increased its holdings in shares of Repligen by 2.7% in the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after buying an additional 89 shares in the last quarter. Kensington Investment Counsel LLC lifted its position in shares of Repligen by 1.9% during the 3rd quarter. Kensington Investment Counsel LLC now owns 10,041 shares of the biotechnology company’s stock valued at $1,494,000 after acquiring an additional 184 shares during the last quarter. iSAM Funds UK Ltd bought a new stake in shares of Repligen during the 3rd quarter worth $203,000. Finally, DF Dent & Co. Inc. grew its holdings in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $158.14 on Wednesday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The stock’s 50-day moving average is $143.15 and its two-hundred day moving average is $141.68. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm has a market cap of $8.86 billion, a P/E ratio of -427.41, a PEG ratio of 4.64 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.23 earnings per share. Analysts predict that Repligen Co. will post 1.54 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on RGEN. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday. They issued a “hold” rating and a $165.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday. They issued a “hold” rating and a $165.00 price objective for the company. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, November 22nd. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $185.20.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.